SCHEMBL15034064

SCHEMBL15034064

COc1ccnc(C(=O)N2CCN(C(=O)c3ncn(-c4cccc(Cl)c4)n3)C(C)(C)C2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCKAR P32238 2/20 0.41
CFTR P13569 1/20 0.41
TSHR P16473 2/20 0.39
SLC6A7 Q99884 1/20 0.39
MAPT P10636 5/20 0.38
POLB P06746 2/20 0.38
MGLL Q99685 2/20 0.37
WNK1 Q9H4A3 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 1/20 0.36
HPGD P15428 1/20 0.36
GPR35 Q9HC97 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
GRM5 P41594 1/20 0.35
NOTUM Q6P988 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034067 0.88 GRM5 (0.47) CCKARMGLLWNK1ALDH1A1HPGD
SCHEMBL15034112 0.86 MGLL (0.43) CFTRTSHRSLC6A7MAPTPOLB
SCHEMBL15034093 0.86 WNK1 (0.47) CCKARCFTRSLC6A7MGLLWNK1
SCHEMBL15034041 0.86 GRM5 (0.39) CCKARCFTRTSHRSLC6A7MAPT
SCHEMBL15034103 0.85 MAPT (0.42) CCKARCFTRTSHRSLC6A7MAPT
SCHEMBL15034055 0.85 CCKAR (0.39) CCKARCFTRTSHRSLC6A7MAPT
SCHEMBL15034042 0.85 GRM5 (0.40) CCKARCFTRTSHRSLC6A7MAPT
SCHEMBL15034057 0.85 DRD3 (0.40) CCKARCFTRSLC6A7MAPTPOLB
SCHEMBL15034045 0.84 KCNK3 (0.40) CCKARCFTRTSHRSLC6A7MAPT
SCHEMBL15019972 0.83 SLC6A7 (0.43) TSHRSLC6A7MGLLSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 CCKAR 460/4885CFTR 3753/4885TSHR 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.